FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Cooper Jeffrey H   2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP, Chief Financial Officer (Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE 3. Date of Earliest Transaction (Month/Day/Year) 02/24/2012 (Street) NOVATO, CA 94949 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/24/2012 02/24/2012 M   4,864 A $ 17.54 44,968 D   Common Stock 02/24/2012 02/24/2012 M   41,964 A $ 17.33 86,932 D   Common Stock 02/24/2012 02/24/2012 M   8,708 A $ 17.86 95,640 D   Common Stock 02/24/2012 02/24/2012 M   2,500 A $ 14.39 98,140 D   Common Stock 02/24/2012 02/24/2012 M   25,000 A $ 21.51 123,140 D   Common Stock 02/24/2012 02/24/2012 S   83,036 D $ 35.069 (1) 40,104 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (right to buy) Comon Stock

$ 17.54

02/24/2012

02/24/2012

M

4,864

05/20/2006(2)

11/19/2016

Common Stock

4,864

$ 17.54

257,214

D

Stock Option (right to buy) Common Stock

$ 17.33

02/24/2012

02/24/2012

M

41,964

12/07/2007(3)

06/06/2017

Common Stock

41,964

$ 17.33

215,250

D

Stock Option (right to buy) Common Stock

$ 17.86

02/24/2012

02/24/2012

M

8,708

05/17/2008(4)

12/16/2018

Common Stock

8,708

$ 17.86

206,542

D

Stock Option (right to buy) Common Stock

$ 14.39

02/24/2012

02/24/2012

M

2,500

11/12/2009(5)

05/11/2019

Common Stock

2,500

$ 14.39

204,042

D

Stock Option (right to buy) Common Stock

$ 21.51

02/24/2012

02/24/2012

M

25,000

11/12/2010(6)

05/11/2020

Common Stock

25,000

$ 21.51

179,042

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Cooper Jeffrey H C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			SVP, Chief Financial Officer

Signatures

Laura Randall Woodhead, Attorney-in-Fact		02/28/2012
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The price in Column 4 is a weighted average price. The prices actually received ranged from $34.88 to $35.29. The reporting person will provide to the issuer, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(2)	Original option grant vested 6/48ths on May 20, 2007 and 1/48th on the 12th of every month thereafter.
(3)	Original option grant vested 6/48ths on December 7, 2007 and 1/48th on the 12th of every month thereafter.
(4)	Original option grant vested 6/48ths on May 17, 2009 and 1/48th on the 12th of every month thereafter.
(5)	Original option grant vested 6/48ths on November 12, 2009 and 1/48th on the 12th of every month thereafter.
(6)	Original option grant vested 6/48ths on November 12, 2010 and 1/48th on the 12th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.